Chimeric Antigen Receptor-Macrophage Therapy Enters the Clinic: The First-in-Human Trial for HER2+ Solid Tumors

Wenxue Ma; Catriona Jamieson

doi:10.1002/mco2.70374

MedComm ›› 2025, Vol. 6 ›› Issue (9) : e70374 DOI: 10.1002/mco2.70374

HIGHLIGHT

Chimeric Antigen Receptor-Macrophage Therapy Enters the Clinic: The First-in-Human Trial for HER2⁺ Solid Tumors

Wenxue Ma ¹
, Catriona Jamieson ¹^,²

Author information +

History +

PDF

Cite this article

Download citation ▾

Wenxue Ma, Catriona Jamieson. Chimeric Antigen Receptor-Macrophage Therapy Enters the Clinic: The First-in-Human Trial for HER2⁺ Solid Tumors. MedComm, 2025, 6(9): e70374 DOI:10.1002/mco2.70374

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	K. A. Reiss, M. G. Angelos, E. C. Dees, et al., “CAR-Macrophage Therapy for HER2-overexpressing Advanced Solid Tumors: A Phase 1 Trial,” Nature Medicine 31, no. 4 (2025): 1171-1182.

[2]	J. Li, P. Chen, and W. Ma, “The Next Frontier in Immunotherapy: Potential and Challenges of CAR-Macrophages,” Experimental Hematology & Oncology 13, no. 1 (2024): 76.

[3]	S. Pierini, R. Gabbasov, M. C. Oliveira-Nunes, et al., “Chimeric Antigen Receptor Macrophages (CAR-M) Sensitize HER2⁺ Solid Tumors to PD1 Blockade in Pre-Clinical Models,” Nature Communications 16, no. 1 (2025): 706.

[4]	Y. Liu, H. Tan, J. Dai, et al., “Targeting Macrophages in Cancer Immunotherapy: Frontiers and Challenges,” Journal of Advanced Research (2025): S2090-1232(24)00622-2.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.